Genotype B and Younger Patient Age Associated with Better Response to Low-Dose Therapy: A Trial with Pegylated/Nonpegylated Interferon- -2b for Hepatitis B e Antigen--Positive Patients with Chronic Hepatitis B in China | Zendy

Hong Zhao | Zendy; Fuat Kurbanov | Zendy; M.-B. Wan | Zendy; Y.-K. Yin | Zendy; Jun Niu | Zendy; Jin Hou | Zendy; Lihui Wei | Zendy; G.-Q. Wang | Zendy; Yasuhito Tanaka | Zendy; M. Mizokami | Zendy; Si Chen | Zendy

Open Access

Genotype B and Younger Patient Age Associated with Better Response to Low-Dose Therapy: A Trial with Pegylated/Nonpegylated Interferon- -2b for Hepatitis B e Antigen--Positive Patients with Chronic Hepatitis B in China

Author(s) -

Hong Zhao,

Fuat Kurbanov,

M.-B. Wan,

Y.-K. Yin,

Jun Niu,

Jin Hou,

Lihui Wei,

G.-Q. Wang,

Yasuhito Tanaka,

M. Mizokami,

Si Chen

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/511042

Subject(s) - medicine , pegylated interferon , chronic hepatitis , immunology , genotype , alpha interferon , hepatitis c , virology , interferon , ribavirin , virus , gene , genetics , biology

Cost and clinically significant adverse effects are the major limiting factors of interferon (IFN) use in therapy for chronic hepatitis B virus (HBV) infection. A clinical trial was conducted in China to study the efficiency and clinical relevance of low-dose regimen of IFN treatment for chronic HBV infection and to reveal factors predicting sustained combined response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research